Vivos Therapeutics, Inc. (VVOS) Revenue History
Annual and quarterly revenue from 2018 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
VVOS Revenue Growth
Revenue Breakdown (FY 2024)
VVOS's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
VVOS Revenue Analysis (2018–2024)
As of May 8, 2026, Vivos Therapeutics, Inc. (VVOS) generated trailing twelve-month (TTM) revenue of $17.3 million, reflecting explosive growth of +75.7% year-over-year. The most recent quarter (Q3 2025) recorded $6.8 million in revenue, up 77.6% sequentially.
Looking at the longer-term picture, VVOS's 5-year compound annual growth rate (CAGR) stands at +5.7%, indicating steady revenue expansion. The company achieved its highest annual revenue of $16.9 million in 2021.
Revenue diversification analysis shows VVOS's business is primarily driven by Product (30%), Service (28%), and Appliances (22%).
When compared to Healthcare sector peers including ALGN (+2.9% YoY), INVA (+13.6% YoY), and RMTI (+17690.7% YoY), VVOS has underperformed the peer group in terms of revenue growth. Compare VVOS vs ALGN →
VVOS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VVOSCurrent | $17M | +75.7% | +5.7% | -74.3% | |
 ALGN | $4.0B | +2.9% | +10.3% | 15.3% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 RMTI | $69M | +17690.7% | +2.2% | -6.8% | |
 DXCM | $4.7B | +16.2% | +19.3% | 19.6% | |
 XRAY | $3.7B | -1.0% | +2.0% | 6.8% |
VVOS Historical Revenue Data (2018–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $15.0M | +8.9% | $9.0M | 60.0% | $-11,171,000 | -74.3% |
| 2023 | $13.8M | -13.9% | $8.3M | 59.9% | $-17,296,000 | -125.3% |
| 2022 | $16.0M | -5.1% | $10.0M | 62.5% | $-25,031,000 | -156.2% |
| 2021 | $16.9M | +29.2% | $12.6M | 74.6% | $-19,471,000 | -115.3% |
| 2020 | $13.1M | +14.7% | $10.4M | 79.7% | $-8,709,129 | -66.7% |
| 2019 | $11.4M | +200.4% | $8.7M | 76.0% | $-10,577,233 | -92.8% |
| 2018 | $3.8M | - | $2.7M | 71.5% | $-8,336,182 | -219.8% |
See VVOS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VVOS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VVOS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVVOS — Frequently Asked Questions
Quick answers to the most common questions about buying VVOS stock.
Is VVOS's revenue growth accelerating or slowing?
VVOS revenue is accelerating at +75.7% year-over-year, exceeding the 5-year CAGR of +5.7%. TTM revenue reached $17M. Growth momentum has increased versus prior periods.
What is VVOS's long-term revenue growth rate?
Vivos Therapeutics, Inc.'s 5-year revenue CAGR of +5.7% reflects the sustained expansion pattern. Current YoY growth of +75.7% is above this long-term average.
How is VVOS's revenue distributed by segment?
VVOS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2024 are available for download. Segment mix reveals concentration and diversification trends.